Ubrogepant

Category: pharmacological

Aliases: Ubrelvy

Pharmacological Mechanism

Small-molecule CGRP receptor antagonist for acute migraine. Same trigeminovascular CLR/RAMP1 receptor target as rimegepant; shorter half-life. CYP3A4 substrate — strong inhibitors contraindicated.

Half-Life (t½)

PO: 6h

Dosing Guidelines

• PO: Typical 100mg (Range: 50 - 100 mg)

Target Organ Systems

• nervous
• digestive